NANO Intrinsic Valuation and Fundamental Analysis - Nanobiotix SA - Alpha Spread

Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 4.47 EUR -0.67%
Market Cap: 211.9m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Intrinsic Value

NANO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NANO stock under the Base Case scenario is 6.07 EUR. Compared to the current market price of 4.47 EUR, Nanobiotix SA is Undervalued by 26%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NANO Intrinsic Value
6.07 EUR
Undervaluation 26%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Nanobiotix SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NANO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NANO?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Nanobiotix SA

Provide an overview of the primary business activities
of Nanobiotix SA.

What unique competitive advantages
does Nanobiotix SA hold over its rivals?

What risks and challenges
does Nanobiotix SA face in the near future?

Summarize the latest earnings call
of Nanobiotix SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nanobiotix SA.

Provide P/S
for Nanobiotix SA.

Provide P/E
for Nanobiotix SA.

Provide P/OCF
for Nanobiotix SA.

Provide P/FCFE
for Nanobiotix SA.

Provide P/B
for Nanobiotix SA.

Provide EV/S
for Nanobiotix SA.

Provide EV/GP
for Nanobiotix SA.

Provide EV/EBITDA
for Nanobiotix SA.

Provide EV/EBIT
for Nanobiotix SA.

Provide EV/OCF
for Nanobiotix SA.

Provide EV/FCFF
for Nanobiotix SA.

Provide EV/IC
for Nanobiotix SA.

Show me price targets
for Nanobiotix SA made by professional analysts.

What are the Revenue projections
for Nanobiotix SA?

How accurate were the past Revenue estimates
for Nanobiotix SA?

What are the Net Income projections
for Nanobiotix SA?

How accurate were the past Net Income estimates
for Nanobiotix SA?

What are the EPS projections
for Nanobiotix SA?

How accurate were the past EPS estimates
for Nanobiotix SA?

What are the EBIT projections
for Nanobiotix SA?

How accurate were the past EBIT estimates
for Nanobiotix SA?

Compare the revenue forecasts
for Nanobiotix SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nanobiotix SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nanobiotix SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nanobiotix SA compared to its peers.

Compare the P/E ratios
of Nanobiotix SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Nanobiotix SA with its peers.

Analyze the financial leverage
of Nanobiotix SA compared to its main competitors.

Show all profitability ratios
for Nanobiotix SA.

Provide ROE
for Nanobiotix SA.

Provide ROA
for Nanobiotix SA.

Provide ROIC
for Nanobiotix SA.

Provide ROCE
for Nanobiotix SA.

Provide Gross Margin
for Nanobiotix SA.

Provide Operating Margin
for Nanobiotix SA.

Provide Net Margin
for Nanobiotix SA.

Provide FCF Margin
for Nanobiotix SA.

Show all solvency ratios
for Nanobiotix SA.

Provide D/E Ratio
for Nanobiotix SA.

Provide D/A Ratio
for Nanobiotix SA.

Provide Interest Coverage Ratio
for Nanobiotix SA.

Provide Altman Z-Score Ratio
for Nanobiotix SA.

Provide Quick Ratio
for Nanobiotix SA.

Provide Current Ratio
for Nanobiotix SA.

Provide Cash Ratio
for Nanobiotix SA.

What is the historical Revenue growth
over the last 5 years for Nanobiotix SA?

What is the historical Net Income growth
over the last 5 years for Nanobiotix SA?

What is the current Free Cash Flow
of Nanobiotix SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nanobiotix SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nanobiotix SA

Current Assets 87.3m
Cash & Short-Term Investments 75.3m
Receivables 9.5m
Other Current Assets 2.6m
Non-Current Assets 6.6m
Long-Term Investments 299k
PP&E 6.3m
Intangibles 8k
Current Liabilities 49.9m
Accounts Payable 173k
Accrued Liabilities 7.4m
Other Current Liabilities 42.3m
Non-Current Liabilities 45.9m
Long-Term Debt 43.7m
Other Non-Current Liabilities 2.2m
Efficiency

Earnings Waterfall
Nanobiotix SA

Revenue
36.2m EUR
Operating Expenses
-61.3m EUR
Operating Income
-25.1m EUR
Other Expenses
-8.4m EUR
Net Income
-33.5m EUR

Free Cash Flow Analysis
Nanobiotix SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Nanobiotix reported significant progress in its partnership with Janssen to develop NBTXR3, a potential first-in-class radioenhancer for solid tumors. This collaboration, potentially worth over $2.5 billion, has already triggered a $20 million milestone payment. The company’s cash balance for Q1 2024 stands at €58.9 million, extending the runway to Q3 2025. Key initiatives include transitioning the Phase III head and neck cancer trial sponsorship to Janssen, which received FDA approval to proceed with a Phase II lung cancer study. Beyond NBTXR3, Nanobiotix is advancing its Curadigm and Oocuity platforms for broader applications in cancer therapy.

What is Earnings Call?
Fundamental Scores

NANO Profitability Score
Profitability Due Diligence

Nanobiotix SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
Exceptional ROE
ROE is Increasing
47/100
Profitability
Score

Nanobiotix SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

NANO Solvency Score
Solvency Due Diligence

Nanobiotix SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
40/100
Solvency
Score

Nanobiotix SA's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NANO Price Targets Summary
Nanobiotix SA

Wall Street analysts forecast NANO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NANO is 11.83 EUR with a low forecast of 9.6 EUR and a high forecast of 16.8 EUR.

Lowest
Price Target
9.6 EUR
115% Upside
Average
Price Target
11.83 EUR
165% Upside
Highest
Price Target
16.8 EUR
276% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NANO?

Click here to dive deeper.

Dividends

Nanobiotix SA
does not pay dividends
Shareholder Yield

Current shareholder yield for NANO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Nanobiotix SA Logo
Nanobiotix SA

Country

France

Industry

Biotechnology

Market Cap

212m EUR

Dividend Yield

0%

Description

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Contact

ILE-DE-FRANCE
Paris
60 rue de Wattignies
+33140260470.0
www.nanobiotix.com

IPO

2012-10-29

Employees

100

Officers

See Also

Discover More
What is the Intrinsic Value of one NANO stock?

The intrinsic value of one NANO stock under the Base Case scenario is 6.07 EUR.

Is NANO stock undervalued or overvalued?

Compared to the current market price of 4.47 EUR, Nanobiotix SA is Undervalued by 26%.

Back to Top